Alcon Laboratories, Inc.

Alcon, Inc.

Alcon Universal Ltd.

Alcon Research, Ltd.

Alcon Manufacturing, Ltd.

Shire Orphan Therapies Gmbh

Novartis Ag

A. H. Robins Company, Incorporated

Other

American Home Products Corporation

Astellas Pharma Gmbh

Kalypsys, Inc.

Shire Orphan Thereapies Gmbh

Takeda Pharmaceutical Company Limited

Mark R Hellberg

Peter G Klimko

Steven T Miller

Gustav Graff

Robert J Collier, Jr

Paul W Zinke

Jon C Nixon

Zixia Feng

John M Yanni

Daniel A Gamache

Thomas R Dean

Verney L Sallee

Iok-Hou Pang

Andrew Rusinko

Ulrich Reineke

Frank Osterkamp

Najam A Sharif

Ulf Reimer

Gerd Hummel

Edgar Specker

Uwe Richter

Heiko Hawlisch

Abdelmoula Namil

Tobias Knaute

Bernadett Simon

Markus Woischnik

Hwang-Hsing Chen

James R Shanklin, Jr

Michael A Kapin

Robert D Selliah

George E Barnes

Jesse Albert May

John E Bishop

William H Garner

Pete Delgado

John Russell Falck

Raymond E Conrow

Bryon Severns

Marjorie F Lou

Jaime E Dickerson, Jr

Abbot F Clark

Steven P Govek

Stewart Alwyn Noble

David P Bingaman

Wan-Heng Wang

Andrew Shiau

Alan John Henderson

Louis M Desantis, Jr

Loretta Graves McNatt

Mark Hadden

Keith D Combrink

David J Thomas

Kenneth C Appell

Karen C David

Cheng Guo

Geoffrey R Owen

Michael L Chandler

Martha E Gadd

Suchismita Mohapatra

Ganesh Prasanna

Clay Beauregard

Peggy Elizabeth Hellberg

Namil Abdelmoula

Andrew Ruskinko

Alan J Henderson

Hélène Y Decornez

Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

NPR-B agonists

Methods of treating ophthalmic diseases using NPR-B agonists

Disclosed are cyclic, peptide-based novel compounds having NPR-B agonistic activity. Preferred compounds are cyclic peptides containing conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. In some embodiments, provided herein are a cyclic peptide compound with a ring size that is significantly reduced as compared to known NPR-B agonists, such as CNP.

Cyclic peptide-based NPR-B agonists

The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topical ocular pharmaceutical composition are also disclosed.

Topical ocular analgesic agents

The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.

Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma

The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

Heteroarylalkoxy-substituted quinolone inhibitors of PDE4

The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.

Superoxide dismutase mimics for the treatment of ocular disorders and diseases

The use of SOD mimics particularly pentaazacycle Mncomplex SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.

The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis.

Method of treating dry eye disorders and uveitis

Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.

3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases

Growing community of inventors

Arlington, TX, United States of America

Mark R Hellberg